Philips is parting ways with its worldwide emergency care business, including its catalog of automated external ...

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

Having shown last week that its opioid alternative can reduce post-surgery pain, Tris Pharma is back with another slice of ...

Imperative Care has received a green light from the FDA for its large-bore catheter to help remove stroke-causing blood clots ...

A judge has ruled against investor Alcon Research on the matter of blocking investee Aurion Biotech from debuting on the ...

BioAge Labs has given up on its lead obesity candidate. Weeks after stopping a trial in response to phase 2 data, the biotech ...

After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...

Two months after launching Pep2Tango Therapeutics, VC firm Versant Ventures is unveiling another obesity-focused biotech in ...

Takeda is taking back the home license for a phase 3-ready depression drug as part of an amendment to its multi-asset ...

Transforming life sciences with AI, powered by Salesforce Life Sciences Cloud | Drug development and commercialization leads ...

Demand slipped for several large contract research organizations last year, and a new report from William Blair analysts suggests these firms should brace for a similar R&D landscape in 2025.

Leap Therapeutics has come crashing down to earth. The biotech axed plans to advance into phase 3 in gastric cancer on the basis of midstage data, sending its stock down 60% to below $1, but it is ...